Posted by Michael Wonder on 07 Feb 2022
Bladder cancer technology: new improved blue light cystoscopy system receives FDA approval for use in non-muscle invasive bladder cancer in the U.S.
7 February 2022 - Photocure announces U.S. FDA approval of a new and improved blue light system to be used with Photocure's Cysview product in blue light cystoscopy procedures for the detection of non-muscle invasive bladder cancer.
Manufactured and soon to be commercialised by Karl Storz Endoscopy-America, the new blue light system is approved for use in procedures requiring rigid cystoscopy.
FDA approval was granted to Karl Storz on 4 February 2022.
